News

This financing was co-led by three new investors including AJU IB Investment Co., Ltd. and two undisclosed private investment groups. The round also includes full participation by all

XmAb5871 is a first-in-class monoclonal antibody containing Xencor’s proprietary immune inhibitor XmAb Fc domain that targets Fc?RIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a

Carried out in agreement to a post-marketing requirement by the US Food and Drug Administration (FDA), the trial showed comparable sexual function in these adults treated daily with

As part of the supplemental deal, Triphase will receive additional development funds through a cost sharing arrangement with Celgene. The deal will see Triphase control product development and

Following approval, this product will serve as replacement therapy for patients who suffer from a congenital lack of the normal plasminogen protein and/or its functional activity. The FDA

OliPass is focused on developing antisense medicines based on peptide nucleic acid (PNA) technology. As part of the deal, BMS will make an up-front payment as well as

The company said that ARA 290 activates the natural repair system of the body by activating the Innate Repair Receptor and thereby turning off systemic inflammation and turning

The trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses MBC-11, a lead compound from a technology platform based on bisphosphonate

Under the deal, Aspen will be responsible for securing regulatory and pricing approval, as well as the marketing and distribution of the drug. Iroko Pharmaceuticals president and CEO